Id: acc0679
Group: 1sens
Protein: HMGB1
Gene Symbol: HMGB1
Protein Id: P09429
Protein Name: HMGB1_HUMAN
PTM: phosphorylation
Site: unclear
Site Sequence:
Disease Category: Cancer
Disease: Gastric Cancer
Disease Subtype:
Disease Cellline: HGC-27
Disease Info:
Drug: Lactate
Drug Info: "Lactate (Lactic Acid) is a hydroxycarboxylic acid receptor 1 (HCAR1) activator, an epigenetic modulator inducing lysine residue lactylation, and a glycolytic end-product involved in antitumor immunity. "
Effect: modulate
Effect Info: "Lactic acid enhances the phosphorylation of HMGB1 via the Akt signaling pathway, promotes the nuclear translocation and release of HMGB1, and induces the proliferation and migration of gastric cancer cells."
Note:
Score: 4.0
Pubmed(PMID): 37968076
Sentence Index:
Sentence:

Sequence & Structure:

MGKGDPKKPRGKMSSYAFFVQTCREEHKKKHPDASVNFSEFSKKCSERWKTMSAKEKGKFEDMAKADKARYEREMKTYIPPKGETKKKFKDPNAPKRPPSAFFLFCSEYRPKIKGEHPGLSIGDVAKKLGEMWNNTAADDKQPYEKKAAKLKEKYEKDIAAYRAKGKPDAAKKGVVKAEKSKKKKEEEEDEEDEEDEEEEEDEEDEDEEEDDDDE

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
HMGB1 CD24FC High mobility group protein B1 inhibitor 3 Completed COVID-19 ClinicalTrials
HMGB1 CD24FC High mobility group protein B1 inhibitor 1 Terminated neoplasm ClinicalTrials
HMGB1 CD24FC High mobility group protein B1 inhibitor 1 Withdrawn metastatic melanoma ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

HMGB1-Ser100
Cancer Intensity
BRCA 0.624
COAD 0.3
HGSC
ccRCC 0.175
GBM 0.87
HNSC -0.067
LUAD -0.054
LUSC 0.075
non_ccRCC -0.653
PDAC 1.165
UCEC -2.436
HMGB1-Ser121
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.521
GBM 0.487
HNSC
LUAD -1.312
LUSC -0.281
non_ccRCC
PDAC -0.013
UCEC 1.64
HMGB1-Ser35
Cancer Intensity
BRCA 1.728
COAD 0.903
HGSC -1.88
ccRCC 0.698
GBM -0.638
HNSC 0.595
LUAD -0.308
LUSC 0.172
non_ccRCC 0.179
PDAC -0.403
UCEC -1.047

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - D Ovarian cancer Acetylation 30058682

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: